

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

**【Cover】**

<b>【Document Submitted】</b>	Extraordinary Report
<b>【Submitted to】</b>	Director, Kanto Local Finance Bureau
<b>【Date of Submission】</b>	June 20, 2025
<b>【Company Name】</b>	Ono Yakuhin Kogyo Kabushiki-Kaisha
<b>【Company Name (in English)】</b>	ONO PHARMACEUTICAL CO., LTD.
<b>【Position and Name of Representative】</b>	Toichi Takino, Representative Director, President and Chief Operating Officer
<b>【Location of Head Office】</b>	1-5, Doshomachi 2-chome, Chuo-ku, Osaka, Japan (The above is the location of the registered head office. The actual head office operations are located at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan.)
<b>【Phone No.】</b>	Not applicable
<b>【Contact for Communications】</b>	Not applicable
<b>【Nearest Contact】</b>	8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan
<b>【Phone No.】</b>	+81-(0)6-6263-5670
<b>【Contact for Communications】</b>	Harumi Nakano, Senior Director, Finance & Accounting
<b>【Place Where Available for Public Inspection】</b>	Tokyo Stock Exchange, Inc. (2-1 Nihombashi Kabutocho, Chuo-ku, Tokyo, Japan)

## 1 【Reason for Filing】

As the following proposals were resolved at the 77th Ordinary General Shareholders' Meeting of Ono Pharmaceutical Co., Ltd. (the "Company") held on June 19, 2025, the Company hereby files this Extraordinary Report pursuant to the provisions of Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and the provisions of Article 19, Paragraph 2, Item 9-2 of the Cabinet Office Ordinance on the Disclosure of Corporate Affairs, etc.

## 2 【Description of Report】

### (1) Date of the Ordinary General Shareholders' Meeting

June 19, 2025

### (2) Details of Proposals Resolved

#### Proposal 1 Appropriation of Surplus

##### Year-End Dividend

##### ① Type of dividend property

Cash

##### ② Allocation of dividend property to shareholders and total amount of such allocation

¥40 per share of common stock      Total dividend amount: ¥18,790,918,760

##### ③ Effective date of the distribution of the dividend

June 20, 2025

#### Proposal 2 Election of Six (6) Members of the Board of Directors

Six (6) Members of the Board of Directors, namely, Gyo Sagara, Toichi Takino, Toshihiro Tsujinaka, Masao Nomura, Akiko Okuno and Shusaku Nagae were elected.

(3) The number of voting rights either approving, disapproving or abstaining on proposals resolved; requirements for the approval of the resolutions and their results

Proposal	For (Number of voting rights)	Against (Number of voting rights)	Abstentions (Number of abstentions)	Requirements for approval	Results Approval ratio (%)
Proposal 1 Appropriation of Surplus	3,805,710	6,828	0	(Note 1)	Approved 99.637
Proposal 2 Election of Six (6) Members of the Board of Directors					
Gyo Sagara	3,330,227	473,303	12,102	(Note 2)	Approved 87.117
Toichi Takino	3,411,871	403,761	0		Approved 89.253
Toshihiro Tsujinaka	3,534,345	281,294	0		Approved 92.457
Masao Nomura	3,660,768	154,873	0		Approved 95.764
Akiko Okuno	3,663,363	152,280	0		Approved 95.832
Shusaku Nagae	3,660,819	154,823	0		Approved 95.765

Notes) 1. Proposal 1 requires approval by a majority of voting rights of the shareholders in attendance eligible for exercising voting rights.

2. Proposal 2 requires the attendance of shareholders holding one-third or more of voting rights owned by shareholders eligible for exercising voting rights and approval by the majority of said voting rights.

(4) The reason why a portion of the voting rights held by the shareholders in attendance at the Ordinary General Shareholders' Meeting was not counted

Resolutions of all the proposals have been legitimately reached in accordance with the Companies Act, as the requirements for approval have been met based on the number of confirmed votes of approval or disapproval by counting the voting rights exercised up to the day before this General Shareholders' Meeting and those of shareholders in attendance. Therefore, voting rights of the shareholders in attendance which are not confirmed as to whether they are approving, disapproving, or abstaining are not included in the count.